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ABSTRACT 
Congenital hypothyroidism (CH) is the most frequent endocrine-metabolic disease in infancy, with an incidence of about 1/2500 newborns [1, 2]. 
In the last 20-30 years the incidence of congenital hypothyroidism in newborns has increased from 1:4000 to 1:2000 [3, 4]. This phenomenon 
could be explained by using a lower b-TSH cutoff, that allowed the detection of an unsuspected number of children with neonatal 
hypothyroidism [5]. With the exception of rare cases due to hypothalamic or pituitary defects, CH is characterized by elevated TSH in response 
to reduced thyroid hormone levels. In absence of an adequate treatment, CH determines growth retardation, delays in motor development, and 
permanent intellectual disability. 
Primary CH is determined by alterations occurring during the thyroid gland development (thyroid dysgenesis, TD [6]) or alterations in the thyroid 
hormone biosynthesis pathways (thyroid dyshormonogenesis). Less common causes of CH are secondary or peripheral defects in TSH 
synthesis and/or action, defects in thyroid hormone transport, metabolism, or action [7]. Table 1 shows a summary of the forms of CH with a 
genetic cause. 
In the majority of cases (80-85%), primary permanent CH is associated with TD.  These forms include developmental disorders such as 
athyreosis, ectopy, hemiagenesis or hypoplasia.  
TD occurs mostly as sporadic disease, however a genetic cause has been demonstrated in about 2-5% of the reported cases [8]. Genes 
associated with TD include several thyroid transcription factors expressed in the early phases of thyroid organogenesis (NKX2.1/TITF1, 
FOXE1/TITF2, PAX8, NKX2.5) as well as genes, like the thyrotropin receptor gene (TSHR) expressed later during gland morphogenesis.  
In the remaining 15-20% of cases, CH is caused by inborn errors in the molecular steps required for the biosynthesis of thyroid hormones, and 
generally it is characterized by enlargement of the gland (goiter), presumably due to elevated TSH levels [9]. Generally, thyroid 
dyshormonogenesis shows classical Mendelian recessive inheritance.  
Rarely CH has a central origin, as consequence of hypothalamic and/or pituitary diseases, with reduced production or function of thyrotropin 
releasing hormone (TRH) or thyrotropin hormone (TSH) [10]. For complete coverage of this and all related areas of Endocrinology, please visit 
our FREE on-line web-textbook, www.endotext.org. 
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EPIDEMIOLOGY 
CH is usually a sporadic disease with a frequency of about two girls for each boy [11]. Familial cases occur with a frequency that is 15-fold 
higher than by chance alone [12]. The genetic basis of these familial cases has been established in some, but not all pedigrees [13].  
An increased prevalence of the disease is reported in twins [14], with approximately 12 fold increased incidence compared to singletons, even if 
a discordance rate of 92% between monozygotic (MZ) twins has been observed [15].  
The incidence of CH differs significantly among different ethnicities and regions, ranging from 1 in 30,000 in the African-American population in 
the United States [16, 17] to 1 in 900 in Asian populations in the United Kingdom [18].  
 
CLINICAL MANIFESTATIONS 
In absence of an adequate treatment, severe CH results in serious mental retardation, in motor handicaps as well as in the signs and symptoms 
of impaired metabolism. Before the introduction of a neonatal screening program, congenital hypothyroidism was one of the most frequent 
causes of mental retardation. 
 
The clinically detectable consequences of CH strongly depend on severity and duration of thyroid hormone deprivation, but there is also a large 
individual variability in treatment response.  
In the first four-six months after birth, only untreated patients with severe CH have clinical manifestations. Milder cases can remain 
undiscovered for years. Clinical features of CH are subtle and non-specific during the neonatal period due in part to the passage of maternal 
thyroid hormone across the placenta; however, early symptoms may include: 
 Decreased activity 
 Wide posterior fontanel 
 Poor feeding and weight gain 
 Small stature or poor growth 
 Long-term jaundice 
 Decreased stooling or constipation 
 Hypotonia 
 Hoarse cry 
 Coarse facial features 
 Macroglossia 
 Umbilical hernia 
 Developmental delay 
 Pallor 
 Myxedema 
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 Goiter 
 
Infants with congenital hypothyroidism are usually born at term or after term. Infants with obvious findings of hypothyroidism (eg, macroglossia, 
enlarged fontanelle, hypotonia) at the time of diagnosis have intelligence quotients (IQs) 10-20 points lower than infants without such findings. 
Often, they are described as "good babies" because they rarely cry and sleep most of the time.  
Anemia may occur, due to decreased oxygen carrying requirement. The accumulation of subcutaneous fluid (intracellularly and extracellularly) 
is usually more pronounced in patients with primary (thyroid) hypothyroidism than in those with pituitary hypothyroidism. Thickening of the lips 
and macroglossia is due to increased accumulation of subcutaneous mucopolysaccharides (i.e., glycosaminoglycans). Alteration of the 
mandibular second molars may be the consequence of long-term effects of severe hypothyroidism on craniofacial growth and dental 
development [19]. In addition, histological changes in the vocal cords (VCs) have also been described [20]. A recent study demonstrated that 
CH children diagnosed during neonatal screening and adequately early treated, showed similar vocal and laryngeal characteristics compared to 
children without CH [21]. 
A small but significant number (3-7%) of infants with CH have other birth defects, mainly atrial and ventricular septal defects or other cardiac 
malformations (approximately 10% of infants with CH, compared with 3% in the general population) [22]. 
 
NEONATAL SCREENING 
Most newborn babies with CH have few or no clinical manifestations of thyroid hormone deficiency, and in the majority of cases the disease is 
sporadic. Indeed, it is not possible to predict which infants are likely to be affected by CH. For these reasons, newborn screening programs 
were developed in the mid-1970s to detect this condition as early as possible. The screening consisted in the measurement of thyrotropin (TSH) 
on heel-stick blood specimens.  
Congenital Hypothyroidism was one of the first diseases screened in neonatal screening programs (NS) [23, 24]. Screening programs for CH 
were initially developed in Quebec, Canada, and Pittsburgh, Pennsylvania, in 1974 [25], and have now been establish in almost all over the 
World [26].  
Since the introduction of the screening, prevalence of CH significantly changed ranging from 1:6500 (estimated before of NS program) [27], to 
1:3000 live births in recent years [4]. This fact is probably associated with an increase in the survival of preterm newborns [4, 5], with 
environmental [14], and ethnic factors, as well as with the reduction in the cutoff values [3, 5] used for neonatal TSH. 
Neonatal screening programs allow for early detection and treatment of CH, and have proven to be successful in preventing brain damage.  
Worldwide, most neonatal screening programs are TSH based in the first 3 days of life and effectively detect only thyroidal congenital 
hypothyroidism (CHT), missing the central CH (CCH). This is characterized by an impairment of TSH production, with low circulating thyroid 
hormones and low, improperly normal, or slightly high TSH levels [28].  
Recently, some countries have developed screening methods measuring both T4 and TSH on the same blood spot simultaneously or stepwise 
(“T4+TSH-method”). These methods allowed also the identification of CCH [29-31], however it should be noted that low T4 and normal TSH can 
be also associated with thyroxine-binding globulin (TBG) deficiency, a laboratory condition that requires no treatment. Discriminate between 
these two conditions is crucial [32] and measurements of circulating TBG or other tests may be necessary [33].  
In the past years, the diagnosis of primary CH was made when serum TSH was ≥10 IU/mL, regardless of the T4 concentration. A recent 
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retrospective study including children screened from 2003 to 2010, showed that 9.13% of the children with b-TSH levels between 5 and 10 
IU/mL also developed hypothyroidism [34]. Indeed, the authors suggested to reduce the cut-off for b-TSH to 5 IU/mL. The lower cut-off levels 
allowed the identification of undiagnosed CH cases, however determined significant increases in the number of children to recall, leaded to 
higher costs of the screening and generated anxiety in parents and relatives of healthy babies [35]. Despite these problems, the usage of lower 
TSH cut-off has also been proposed in several other studies [36-38]. 
 
ADDITIONAL TESTS FOR DIAGNOSIS 
When the TSH concentration on a dried blood spot exceeds the established threshold, additional studies can be performed to obtain diagnostic 
confirmation end etiological definition of CH. If these studies will determine a delay in the beginning of the treatment, they should be performed 
later during the babies life. 
Tests commonly used to determine the underlying cause of congenital hypothyroidism are presented in Table 2.  
 
- Thyroid scintigraphy, with 99mtechnetium or 123I, is the most informative diagnostic procedure in patients with thyroid dysgenesis [39, 40] 
providing etiologic diagnosis, as in alteration in the iodine transporter (NIS) [40]. If the radioisotope uptake has not been performed at birth, it is 
necessary performed this imaging screening after 3 years of age, when the T4 treatment interruption does not compromise the neurocognitive 
development of the child [31]. Recently it has been suggested that intramuscular injections of recombinant human TSH can be useful to perform  
123I- uptake studies during L-thyroxine treatment in CH patients [41, 42]. 
 
- Ultrasound represents the gold standard for measuring thyroid dimensions, but lacks sensitivity for detecting small glands and it is less 
accurate than scintigraphy in showing ectopic glands [43]. Moreover, visualization of neonatal thyroid on ultrasound may be challenging for 
unexperienced sonographists [44].  
More than 80% of newborn infants with TSH elevation can be diagnosed correctly on initial imaging with combined radioisotope scan and 
ultrasound.  
 
- Assay of serum thyroglobulin (Tg) will be useful in to establish the presence of some thyroid tissue. 
- More specialized tests, such as perchlorate discharge, evaluation of serum, salivary, and urinary radioiodine [45], and measurement of serum 
T4 precursors, may be necessary to delineate specific inborn errors of thyroid hormone biosynthesis [46].  
- When both the maternal and fetal thyroid glands are compromised, significant cognitive delay can occur despite early and aggressive 
postnatal therapy. Maternal thyrotropin-stimulating hormone receptor (TSHR)-blocking antibodies (Abs) can be transmitted to the fetus and 
cause combined maternal-fetal hypothyroidism. Measurement of TSHR Abs is necessary to establish the diagnosis; the presence of other 
thyroid Abs is insufficiently sensitive and may miss some cases [47]. 
- The measurement of the total urinary iodine excretion differentiates inborn errors from acquired transient forms of hypothyroidism due to iodine 
deficiency or iodine excess. 
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- A small number of infants with abnormal screening values will have transient hypothyroidism as demonstrated by normal serum T4 and TSH 
concentrations at the conﬁrmatory laboratory tests. Transient hypothyroidism is more frequent in iodine-deﬁcient areas and it is much more 
common in preterm infants. CH can also be the consequence of intrauterine exposure to maternal antithyroid drugs, maternal TSHR-blocking 
antibodies (TSHRBAb), as well as heterozygous DUOX1 and DUOX2 or TSHR germ-line mutations [48, 49]. Because the transient nature of 
the hypothyroidism will not be recognized clinically or through laboratory tests, initial treatment will be similar to that of the infant with permanent 
CH, however at a later age interruption of therapy allows to distinguish transient from permanent hypothyroidism [50]. 
 
GENETIC CLASSIFICATION OF CONGENITAL THYROID DISEASES 
 
1. Central hypothyroidism 
Congenital central hypothyroidism (CCH) is a rare disease in which thyroid hormone deficiency is caused by insufficient thyrotropin (TSH) 
stimulation of a normally-located thyroid gland. Patients with this disorder cannot be identified by neonatal screening program based on the 
measurement of TSH alone, while combined assay of T4 and TSH will allow the identification of patients with CCH [29, 32, 51]. 
Initially the incidence was estimated between 1:29.000 and 1:110.000 [52-54], while the more recent study from the Netherlands suggests that it 
may occur in 1:16.000 newborns, representing up to 13% of cases of permanent congenital hypothyroidism [55, 56].  
So far, rare genetic defects have been identified in patients affected by CCH. The disorder can be caused by mutations in genes involved in 
pituitary development such as POU1F1, PROP1, HESX1, LHX3, LHX4 and SOX3. In these cases, central hypothyroidism does not occur in 
isolation, but is one of the evolving pituitary hormone deficiencies [57]. 
In contrast, the isolated CCH is determined by mutations in genes specific to the hypothalamic-pituitary-thyroid axis such as: TSHB (encoding 
the B-subunit of the TSH glycoprotein hormone), TRHR (the specific 7-transmembrane domain receptor for hypothalamic thyrotropin-releasing 
hormone [58]), IGSF1 (a protein regulating the expression of TRHR in pituitary thyrotropes) [59], and the recently identified TBL1X (a subunit of 
the NCoR-SMRT complex) [60]. 
 
1.1 Developmental defects of the pituitary 
The pituitary gland is formed from an invagination of the floor of the third ventricle and from Rathke’s pouch, developing into the thyrotropic cell 
lineage and the four other neuroendocrine cell types, each defined by the hormone produced: TSH, growth hormone (GH), prolactin, 
gonadotropins (luteinizing hormone [57] and follicle-stimulating hormone [61]), and adrenocorticotropic hormone (ACTH). 
The ontogeny of the pituitary gland depends on numerous developmental genes that guide differentiation and proliferation. These genes are 
highly conserved among species, suggesting crucial evolutionary roles for the proteins (PIT1 and PRPO1, HESX1, LHX3, LHX4 and SOX3).  
 
Lhx3 and Lhx4 belong to the LIM family of homeobox genes that are expressed early in Rathke’s pouch. In Lhx3 knockout mice the thyrotropes, 
somatotropes, lactotropes, and gonadotropes cell lineages are depleted, whereas the adrenocorticotropic cell lineage fails to proliferate. This 
murine knock out model shows that pituitary organ fate commitment depends on Lhx3. Lhx4 null mutants show Rathke’s pouch formation with 
expression of a glycoprotein subunit, TSH-beta, GH and Pit1 transcripts, although cell numbers are reduced.  
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In humans, homozygous or compound heterozygous carriers of LHX3 mutations present with combined pituitary hormone deficiency diseases 
and cervical abnormalities with or without restricted neck rotation. Some patients also present with sensorineural hearing loss. Mutations can 
also be frameshift or splicing anomalies. In addition, the heterozygous carriers of a dominant negative LHX3 mutation are characterized by 
limited rotation of the neck.  Patients with heterozygous missense or frameshift mutations in LHX4 have variable phenotypes, including GH 
disease and variable TSH, gonadotropin and ACTH deficiencies with a hypoplastic anterior pituitary, with or without an ectopic posterior pituitary 
[62, 63]. 
 
Hesx1 (also called Rpx), a member of the paired-like class of homeobox genes, is one of the earliest markers of the pituitary primordium [64]. 
Extinction of Hesx1 is important for activation of downstream genes such as Prop1, suggesting that the proteins act as opposing transcription 
factors [65]. Targeted disruption of Hesx1 in the mouse revealed a reduction in the prospective forebrain tissue, absent optic vesicles, markedly 
decreased head size, and severe microphthalmia. A similar phenotype it has been observed in patients with the syndrome of septo-optic 
dysplasia (SOD). SOD is a complex and highly variable disorder, diagnosed in the presence of: 1) optic nerve hypoplasia, 2) midline 
neuroradiologic abnormalities and/or 3) anterior pituitary hypoplasia with consequent hypopituitarism [62]. The number of genetic factors 
implicated in this condition is increasing and currently includes HESX1, OTX2, SOX2 and SOX3. These genes are expressed very early in 
forebrain and pituitary development and so it is not surprising that mutations affecting these genes can induce the SOD disorders.  
Very recently Sonic hedgehog (Shh) has been associated to SOD, since mouse embryos lacking in the gene exhibit key features of the disease, 
including pituitary hypoplasia and absence of the optic disc [66]. 
The human HESX1 gene maps to chromosome 3p21.1–3p21.2, and its coding region spans 1.7 Kb, with a highly conserved genomic 
organization consisting of four coding exons. The ﬁrst homozygous missense mutation (Arg160Cys) was found in the homeobox of HESX1 in 
two siblings with SOD [64]. Subsequently several other homozygous and heterozygous mutations have been shown to present with different 
phenotypes characterized by pituitary hormone deficiency and SOD [65, 67].  
 
1.2 Defects in the TRH and TRH receptor 
The TRH receptor (TRHR) is a G-protein- coupled receptor located at pituitary thyrotropes and activated by hypothalamic TRH. The synthesis, 
secretion, and bioactivity of TSH necessary for following production of thyroid hormones, depend by TRH-TRHR signaling [59].  
In mice, homozygous deletion of the TRH gene produced a phenotype characterized by hypothyroidism and hyperglycemia [68]. Only a few 
patients with reduced TRH production have been described in the literature [69, 70], but no human mutations have been identified so far. 
Mice lacking the TRH receptor appear almost normal, with some growth retardation, and decreased serum T3, T4, and prolactin (PRL) levels but 
normal serum TSH [71]. So far, four mutations in TRHR gene were identified in human. In the first case, the patient was a compound 
heterozygote for an early stop codon (p.R17X) and an in-frame deletion added to a missense change (p.S115- T117del + p.A118T) in the other 
allele [58]. The same p.R17X mutation was found also in the second patient in homozygous state  [72], whereas the third exhibited a 
homozygous missense mutation (p.P81R) [73]. More recently has been identified in a consaguineous family a homozygous missense mutation 
(c.392T>C; p.I131T) located at a highly conserved hydrophobic position of G-protein-coupled receptor, which reduces the affinity for TRH, 
compromising the signal trasduction [74]. The same mutation, was present in the mother, two brothers and grandmother, but in heterozygous 
status leading to isolated hyperthyrotropinemia. 
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1.3 Defects in Thyroid-Stimulating Hormone (TSH) synthesis 
The thyroid stimulating hormone (TSH) is produced and secreted by the thyrotrophic cells of the anterior pituitary gland and it is the classic 
ligand for the TSH receptor (TSHR) in the thyroid. TSH is a heterodimeric glycoprotein consisting of an α subunit and β subunit, The α subunit is 
shared with other glycoprotein hormones (i.e. follicle-stimulating hormone (FSH), luteinizing hormone (LH), and chorionic gonadotropin (CG)), 
whereas the TSHβ subunit is unique, determining the specificity of TSH. The beta-subunit (gene map locus 1p13) synthesis is under the control 
of several transcription factors, including POU1F1 and PROP1. 
 
Pit1/POU1F1 
Pit1 (called POU1F1 in humans) is a pituitary-speciﬁc transcription factor belonging to the POU homeodomain family. The human POU1F1 
maps to chromosome 3p11 and consists of six exons spanning 17 Kb encoding a 291 aminoacid protein.  
Identified mutations of the POU1F1 gene in human result in combined pituitary hormone deficiency (CPHD) with an incidence between 38% and 
77% in unselected cohorts, and between 25% and 52% in patients with a family history of CPHD. To date, several recessive and six dominant 
POU1F1 gene mutations have been described in CPHD patients and include missense, nonsense, frameshift, whole gene deletion and two 
mutations that result in the mis-splicing of the pre-mRNA [75, 76].  
Deﬁciency of GH, prolactin and TSH is generally severe in patients harbouring mutations in POU1F1. The patients are often affected by 
extreme short stature, learning difficulties, and anterior pituitary hypoplasia [76]. 
 
PROP1 
Prop1 (Prophet of Pit1) is a pituitary-speciﬁc paired-like homeodomain transcription factor required for the expression of Pit1, and transcriptional 
activator to stimulate pituitary cell differentiation. Dwarf mice, harboring a homozygous missense mutation in Prop1, exhibit GH, TSH and 
prolactin deﬁciency, and an anterior pituitary gland reduced in size by about 50%. Additionally, these mice have reduced gonadotropin 
expression [77]. 
The human PROP1 maps to chromosome 5q. The gene consists of three exons encoding for a 226 aminoacids protein. After the first report of 
mutations in PROP1 in four unrelated pedigrees with GH, TSH, prolactin, LH and FSH deﬁciencies [78], several distinct mutations have been 
identiﬁed in over 170 patients [65], suggesting that mutations in PROP1 are the most prevalent cause of multiple pituitary hormone deficiency, 
accounting for up to 50% of familial cases, although the incidence of PROP1 mutations is much lower in sporadic cases [62]. 
Affected individuals exhibit recessive inheritance [67]. The timing of initiation and the severity of hormonal deﬁciency in patients with PROP1 
mutations is highly variable: diagnosis of GH deficiency preceded that of TSH deficiency in 80%. Following the deficiencies in GH and TSH, 
there is a reduced fertility due to gonadotropin insufficiency. Although most patients fail to enter puberty spontaneously, some start puberty 
before deficiencies in LH and FSH evolve. ACTH deficiency is a relatively late manifestation of PROP1 mutation, often evolving several 
decades after birth. The degree of prolactin deficiency and pituitary morphological alterations are variable [65].  
  
1.4 Structural Thyroid-Stimulating Hormone defects 
Mutation in the TSH-beta gene are a rare cause of congenital hypothyroidism. Available data have been reviewed by Miyai [79, 80].  
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Several mutations in TSHB gene were identified in the last years, including missense, non-sense, frameshift and splice-site. The most 
commonly reported mutation is the C105Vfs114X mutation, located on exon 3 of the TSHB gene, and firstly described in 1996 [81]. In all the 
reported cases, the mutations were homozygous or compound heterozygous. So far, no genotype-phenotype correlation has been reported. 
The patients present all clinical sign of hypothyroidism, and the severity of the pathology depend by start of treatment. Very recently [82], direct 
sequencing of the coding region of the TSHB gene revealed two homozygous nucleotide changes. The first C.40A>G (rs10776792) is a 
recurrent alteration that can also be found in healthy individuals. The other variation was c.94G>A at codon 32 of exon 2, which results in a 
change of glutamic acid to lysine (p.E32K). For both variations, both patients were homozygous and the parents were heterozygous. 
 
 
1.5 Deficiency of immunoglobulin superfamily member 1 (IGSF1) 
IGSF1 is a plasma membrane immunoglobulin superfamily glycoprotein [83, 84]. Human IGSF1 and murine Igsf1 mRNAs are highly expressed 
in Rathke’s pouch and in adult pituitary gland and testis. Moreover, IGSF1 protein is expressed in murine thyrotropes, somatotropes, and 
lactotropes, but not in gonadotropes or in the testis [85]. Igsf1 knockout mice showed no alternation of follicle stimulating hormone synthesis or 
secretion, and normal fertility [61]. 
The physiological role of IGSF1 is unknown, but it’s lack is responsible for a variety of symptoms such as hypothyroidism, prolactin deficiency, 
macroorchidism and delayed puberty. IGSF1 is important for the pituitary-thyroid axis and the development puberty and thus represents a new 
player controlling growth and puberty in childhood and adolescence. So far, 10 distinct IGSF1 mutations have been described in 26 patients 
[85], one deletion in male patient [86], and other six mutations have been identified in Japanese subjects [87-90]. Recently, a novel insertion 
mutation, c.2284_2285insA [91], has been discovered by whole-exome sequencing in three siblings affected by mild neurological phenotype. 
The mutations included in-frame deletions, single nucleotide deletions, nonsense mutations, missense mutations and one single-base 
duplication. In vitro expression studies of several mutations done to analyze the functional consequences demonstrated that the encoded 
proteins migrated predominantly as immature glycoforms and were largely retained in the endoplasmic reticulum, resulting in decreased 
membrane expression [85]. It is likely that there is no clear genotype-phenotype correlation. Even in familial cases sharing the same IGSF1 
defects, a variable degree of hypothyroidism was observed [85, 92]. Other genetic or environmental factors may influence the phenotypic 
expression of IGSF1 deficiency. 
 
1.6 TBLX1 
TBL1X, transducin β-like protein 1 X-linked, is a part of the nuclear receptor corepressor (NCoR)-silencing mediator for retinoid and thyroid 
hormone receptors (SMRT) complex. In mice, the reduction of TH synthesis can be caused by disruption of NCoR, while the peripheral 
sensitivity to TH increases [93]. Initially, TBL1X gene mutations in humans were associated to hearing loss [94], but not to CCH, but Heinen & 
co recently identified six novel missense mutations in eight patients diagnosed with isolated CCH and hearing defects [60]. Functional studies 
demonstrated that the mutations cause an aberrant protein folding and stability, altering the structural and functional properties of TBLX1. 
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2. Alterations of thyroid morphogenesis (thyroid dysgenesis) 
Thyroid dysgenesis (TD) is the most frequent form (~ 75%) of primary permanent congenital hypothyroidism (CH). TD includes several 
disorders caused by errors during thyroid development, such as athyreosis (absent gland), hypoplasia (reduced gland) or ectopy (gland located 
in aberrant position) [46].  
The most critical events in thyroid organogenesis occur during the first 60 days of gestation in man and the first 15 days in mice. It is likely that 
alterations in the molecular events occurring during this period can be associated to TD. Studies on thyroid development in normal and mutated 
mouse embryos indicate that the simultaneous presence of Pax8, Nkx2-1, Foxe1, and Hhex is required for thyroid morphogenesis. Indeed, 
thyroid dysgenesis is present in animal models with mutations in these genes, and mutations in the same genes have been identified in patients 
with congenital hypothyroidism associated with TD. 
 
2.1 Athyreosis 
Athyreosis is the absence of thyroid follicular cells (TFC) in orthotopic or ectopic location. This condition can either be the consequence of lack 
of formation of the thyroid bud or results from alterations in any of the step following the specification of the thyroid bud and determining a 
defective survival and/or proliferation of the precursors of the TFC. In athyreotic patients, the presence of cystic structures resulting from the 
persistence of remnants of the thyroglossal duct is frequently reported. This finding indicates that in these subjects some of the early events of 
thyroid morphogenesis have taken place but the cells fated to form the TFCs either did not survive or switched to a different fate. In many 
cases, scintigraphy failed to demonstrate the presence of thyroid tissue, but thyroid scanning by ultrasound reveals a very hypoplastic thyroid 
gland. 
So far, the absence of thyroid was reported in 3 patients with CH associated to FOXE1 gene defects (Bamforth-Lazarus syndrome) (p.S57N, 
p.A65V, and p.N132D), in four subjects carrying a mutation in PAX8, in two patients with NKX2-1 mutation, in two patients with NKX2-5 
mutation [8, 95] and in one patient with both a heterozygous NKX2-5 mutation and a heterozygous mutation in the PAX8 promoter region [96]. 
Recently, mutational screening in TSHR, NKX2.1, in FOXE1, in NKX2.5 and in PAX8 was performed in 100 Chinese subjects affected by 
thyroid athyreosis [97]. Several mutations have been identified, but the most of them were previously reported and the bioinformatics analysis 
suggested they were benign with no clinical relevance. Only the TSHR variants have been suggested to have deleterious effects by in silico 
analysis.  
 
2.2 Ectopic thyroid 
The ectopic thyroid is the consequence of a failure in the descent of the developing thyroid from the thyroid anlage region to its definitive 
location in front of the trachea. In the majority of cases, the ectopic thyroid appears as a mass in the back of the tongue (lingual thyroid, usually 
functioning). Sublingual ectopic tissues are less frequent; in this case, thyroid tissue is present in a midline position above, below or at the level 
of the hyoid bone. Ectopic thyroid tissues within the trachea or thyroid tissue in the submandibular region have also been reported. 
The thyroid ectopy is the most common spectrum of thyroid dysgenesis, occurring in up 80% of CH caused by TD, but only the 3% of CH cases 
are explained by inherited mutation in the gene involved in thyroid development.  
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To date, mutational analysis performed in several countries, demonstrated the presence of mutation in patients with thyroid ectopy in NKX2-5 
gene (p.R25C, p.A119S, p.R161P), FOXE1 (p.R102C) and PAX8 (p.R108X, p. T225M, p.R31H) [8, 23].  
Monozygotic (MZ) twins are usually discordant for CH due to thyroid dysgenesis, suggesting that most cases are not caused by transmitted 
genetic variation. One possible explanation could be the onset of somatic mutations in migrating genes after zygotic twinning. However, 
significant somatic methylation profile differences were not observed between ectopic and orthotopic thyroids [98], nor somatic mutations were 
found by exome sequencing of lymphocytic DNA from MZ twins discordant for CHTD [99]. Since the monoallelic genes are more vulnerable to 
other benign monoallelic genetic or epigenetic mutations, the autosomal monoallelic expression (AME) could explain discordance and the 
sporadic nature of CH [100]. The study showed that the AME is observed for some genes in ectopic and orthotopic thyroids. These genes are 
involved in epithelial–mesenchymal transition, cell migration, cancer, and immunity. Therefore, also in this case, no thyroid-specific mutations 
were observed in ectopic tissues in any of the genes normally involved in thyroid development and associated with thyroid dysgenesis. 
Recently, several DUOX2 mutations have been identified in a cohort of 268 children affected by TD (134 of whom were thyroid ectopy cases), 
by whole-exome sequencing (WES). Seven mutations were nere reported before (G201E, L264CfsX57, P609S, M650T, E810X, and M822V, 
and E1017G) while eight (P138L, D506N, H678R, R701Q, A728T, S965SfsX29, P982A, and S1067L) have been previously described [101]. 
These findings suggest that also DUOX2 could play a role in thyroid development. 
 
2.3 Hypoplasia 
Orthotopic and hypoplastic thyroid is reported in 5% of CH cases. Thyroid hypoplasia is a genetically heterogeneous form of thyroid dysgenesis, 
since mutations in NKX2-1, PAX8 or TSHR gene have been reported in patients with thyroid hypoplasia. 
NKX2.1 mutations have been described in several patients with primary CH, respiratory distress and benign hereditary chorea, which are 
manifestations of the “Brain-Thyroid-Lung Syndrome” (BLTS). In the majority of cases haplo-insufficiency has been considered to be 
responsible for the phenotype. Only a few mutations produce a dominant negative effect on the wild type NKX2-1, and among those in two 
cases a promoter-specific dominant negative effect was reported [102]. So far, more than 96 mutations in the NKX2.1 gene have been identified 
[103]. Interestingly, not all mutational carriers display the full phenotype of BLTS but have only involvement of two or even one part of the 
syndrome. Very recently, Hermanns &co [104] described a patient affected by TD with hypoplastic thyroid gland, respiratory disease and 
cerebral palsy who presented mutations in both PAX8 (p.E234K) and NKX2.1 (p.A329GfsX108) genes. Functional studies demonstrated no 
transcriptional activity or DNA-binding of NKX2.1 mutant protein. Contrary the PAX8 mutant protein was normally located into the nucleus, and 
has no functional impairment. These results confirm the role of NKX2.1 mutant protein in the manifestation of the BTLS phenotype and suggest 
that other molecular mechanisms could be causative of the disease.  
NKX2.5 was recently found mutated in patients affected by thyroid hypoplasia and no cardiovascular defects [105]. Both these mutations 
(c.73C>T and c.63A>G) were previously described [106, 107]. The c.73C>T was found in patients affected by thyroid ectopy and without 
congenital heart defects [107] and showed a deficiency in dimer formation without effects on the DNA binding capacity. The c.63A>G did is a 
silent mutation that determines no changes in the aminoacid sequence. It has been reported in a patients with thyroid hypoplasia [108] but also 
in healthy controls [105]. 
The involvement of PAX8 has been described in sporadic and familial cases of CH with thyroid hypoplasia [109-111]. All affected individuals are 
heterozygous for the mutations and autosomal dominant transmission with incomplete penetrance and variable expressivity has been described 
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for the familial cases. In vitro transfection assays demonstrated that the mutated proteins are unable to bind DNA and to drive transcription of 
the TPO promoter. By NGS analysis performed in a cohort of 11 families, a heterozygous PAX8 (p.R31C) was identified in two siblings with CH 
and hypoplastic thyroid [112]. One of the patients also presented unilateral kidney agenesis. The mutation completely inactivates the activity of 
the transcription factor, as previously reported for the p.R31H [113, 114]. The frequent observation of mutation occurring in this aminoacid 
suggested that position 31 in the PAX8 protein can be a mutational hot spot.  
TSHR belongs to the G-protein coupled receptors superfamily. The gene encoding TSHR maps to chromosome 14q31 and to mouse 
chromosome 12. It consists in ten exons codify for a 764 aminoacid protein. The role of the TSHR in thyroid differentiation was first identified in 
Tshr hyt/hyt mice, affected by primary hypothyroidism with elevated TSH and hypoplastic thyroid, as a consequence of a loss of function 
mutation in the fourth transmembrane domain of TSHR (pro556Leu), which abolishes the cAMP response to TSH. Several patients with 
homozygous or compound heterozygous loss-of-function TSHR mutations have been reported. The disease, known as resistance to TSH 
(OMIM #275200) is inherited as an autosomal recessive trait, and patients are characterized by elevated serum TSH levels, absence of goiter 
with a normal or hypoplastic gland, and normal to very low serum levels of thyroid hormones. The clinical manifestations are very variable 
spanning from euthyroid hyperthyrotropinemia to severe hypothyroidism. A novel non-synonymous substitution was recently reported in the 
HinR of the large N-terminal extracellular domain of the TSHR gene in a patient with thyroid hypoplasia. Since this p.S304R TSHR variant does 
not affect the TSH binding nor the cAMP pathway activation, it was not possible to establish his role in the clinical phenotype [23].  
2.4 Hemiagenesis 
Thyroid hemiagenesis (THA) is a rare congenital abnormality, in which one thyroid lobe fails  
to develop. Thyroid hemiagenesis is often associated with mild and/or transient hypothyroidism but several patients were found to be euthyroid.  
The incidence of the disorder is estimated at 0.05–0.5% of the general population. THA occurs usually as an isolated feature, more frequently in 
women than in men. In the large majority of the cases, the left lobe is absent [115]. 
The molecular mechanisms leading to the formation of the two thyroid symmetrical lobes, which are impaired in the case of hemiagenesis, are 
still unclear and in humans. In contrast, Shh-/- mice embryos can display either a non-lobulated gland [116] or hemiagenesis of thyroid [117], 
and hemiagenesis of the thyroid is also frequent in mice double heterozygous Titf1+/-, Pax8+/- [118].  
In the majority of patients with thyroid hemiagenesis, the genetic background remains unknown. Additionally, THA family members commonly 
present other thyroid developmental anomalies (i.e., thyroid agenesis, ectopy or thyroglossal duct cyst), suggesting a common genetic 
background for different thyroid developmental anomalies of the gland.  
Mutations in NKX2.1, PAX8 or FOXE 1 are rarely associated with THA. novel single nucleotide substitution in exon 2 of the PAX8 gene (c.162 
A>T; p.S54C) was recently identified 13/16 members of a family with hypothyroidism and variable phenotype (thyroid hemiagenesis to normal) 
[119].  
FOXE1 contains within its coding sequence a polyalanine tract of variable length, ranging from 11 to 19 alanines [120]. Several studies have 
pointed to the potential role of FOXE1-polyAla length polymorphism in determining the susceptibility to TD [121-123]. 
Avery recent study, demonstrate the potential association between proteasome-related genes and THA. In a cohort of 34 sporadic patients and 
three families with THA several mutations have been identified in proteasome genes PSMA1, PSMA3, PSMD2, and PSMD3. The functional 
studies indicate that the mutations can lead to accumulation of undegraded protein aggregates and exert a toxic effect on the thyroid cell [124].  
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2.5 Other genetics defects 
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Recently, several other genes have been suggested to play a role in the pathogenesis of thyroid dysgenesis, including JAG1, GLIS3, CDCA8 or 
SLC26A4. 
 
2.5.1 GLIS3 
In a rare syndrome, CH can be associated to neonatal diabetes (NDH). These patients exhibit reduced T3 and T4 levels with elevated TSH and 
Tg. Patients additionally develop hyperglycemia and hypo-insulinemia. They often also presented polycystic kidney disease, hepatic fibrosis, 
glaucoma and mild mental retardation. Thyroid ultrasound and scintigraphy suggested athyreosis or hypoplasia. In most of the cases, the 
patients do not respond to conventional treatment and TSH remains elevated, despite normalization of serum T4 levels. This form has been 
associated to GLIS3 mutations [125, 126]. GLIS3 is a transcription factor containing five Krüppel-like zinc finger domains and sharing high 
homology with GLI zinc finger proteins. It has been postulated to have a critical role in the regulation of a variety of cellular processes during 
development [127]. GLIS3 may act as a transcriptional activator or repressor, but its precise role in thyroid development and function remains to 
be determined [128]. So far, few patients with syndromic CH and GLIS3 mutations have been identified [126]. Very recently, a novel GLIS3 
deletion has been published in a CH girl that also presented camptodactyly, syndactyly and polydactyly [129], and mutations have been 
reported in patients with CH and abnormalities in external genitalia, not previously described [130]. 
 
2.5.2 JAG1 
Studies in zebrafish suggested the involvement of Notch pathway in congenital hypothyroid phenotype [131]. In humans, heterozygous JAG1 
variants are known to account for Alagille syndrome type 1 (ALGS1), a rare multisystemic developmental disorder characterized by variable 
expressivity and incomplete penetrance, but a recent study on a cohort of 21 young Alagille patients revealed an increased risk of non-
autoimmune hypothyroidism (28%) in the presence of JAG1 heterozygous mutations [132, 133]. 
 
2.5.3 CDCA8 
Recently, genetic variants in CDCA8 (also called BOREALIN) were identified in a study of three consanguineous families with thyroid 
dysgenesis [134]. The thyroid phenotypes observed in patients carrying CDCA8 variants is extensive, ranging from thyroid agenesis or ectopy 
to euthyroid individuals with asymmetric thyroid lobes or thyroid nodules. This variability makes the role of CDCA8 in thyroid dysgenesis still 
unclear and controversial.  
 
2.5.4 SLC26A4 
Pendrin (SLC26A4, PDS) alterations have been initially associated to Pendred syndrome (see later). Recently, NGS techniques used in patients 
with TD, demonstrated the frequent presence of SLC26A4 mutations also in patients with TD. The mutations were initially identified in a patient 
with hypoplastic thyroid tissue and severe hearing problems [135], but later the prevalence of SLC26A4 mutation was calculated to be 4% 
among studied Chinese CH patients [136]. 
 
2.5.5 DNAJC17 
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Studies on mouse models indicated that neither Pax8 or Nkx2.1 heterozygous null mice showed overt thyroid defects, while double 
heterozygous mice for both Nkx2.1 and Pax8 (DHTP) had a severe hypothyroidism characterized by thyroid hypoplasia or hemiagenesis [118]. 
The DHTP hypothyroid phenotype was strain specific, and the same authors identified in Dnajc17 the strain-related modifier gene for 
hypothyroidism. DNAJC17 belongs to the heat-shock-protein-40 type III family. DNAJC17 proteins interact, via a highly-conserved domain (J 
domain) with Hsp70 chaperone proteins, regulating their activity and controlling the disassembly of transcriptional complexes [137, 138].  
Very recently a DNAJC17 mutational screening has been performed in a cohort of 89 CH patients. The analysis identified only one rare variant 
(c.610G>C) and one polymorphism (c.350A>C) in affected patients. Both variants were already reported in databases and the frequency of the 
alleles was not different between TD patients and controls [139].  
 
3. Defects in thyroid hormone synthesis (dyshormonogenesis) 
In about 15% of cases, CH is due to hormonogenesis defects caused by mutations in genes involved in thyroid hormone synthesis, secretion or 
recycling. These cases are clinically characterized by the presence of goiter, and the molecular mechanisms have been well defined.  
In thyroid follicular cells, iodide is actively transported and concentrated by the sodium iodide symporter present in the baso-lateral membrane. 
Subsequently it is oxidised by hydrogen peroxide generation system (thyroperoxidase, Pendrin) and bound to tyrosine residues in thyroglobulin 
to form iodotyrosine (iodide organification). Some of these iodotyrosine residues (monoiodotyrosine and diiodotyrosine) are coupled to form the 
hormonally active iodothyronines (T4) and triiodothyronine (T3). When needed, thyroglobulin is hydrolyzed and hormones are released in the 
blood. A small part of the iodotyronines is hydrolyzed in the gland, and iodine is recovered by the action of specific enzymes, namely the 
intrathyroidal dehalogenases (Figure 1).  
Defects in any of these steps lead to reduced circulating thyroid hormone, resulting in congenital hypothyroidism and goiter. In most of the 
cases, the mutations in these genes appear to be inherited in autosomal recessive fashion [9].  
 
3.1 Sodium-iodide symporter  
The sodium-iodide symporter (NIS) is a member of the sodium/solute symporter family that actively transports iodide across the membrane of 
the thyroid follicular cells. The human gene (SLC5A5) maps to chromosome 19p13.2-p12. It has 15 exons encoding for a 643-amino acid 
protein expressed primarily in thyroid, but also in salivary glands, gastric mucosa, small intestinal mucosa, lacrimal gland, nasopharynx, thymus, 
skin, lung tissue, choroid plexus, ciliary body, uterus, lactating mammary tissue and mammary carcinoma cells, and placenta. Only in thyroid 
cells iodide transport is regulated by TSH. It has been demonstrated that the δ-amino group at position 124 of NIS protein, is required for the 
transporter’s maturation and cell surface targeting [140].  
The inability of the thyroid gland to accumulate iodine was one of the early known causes of CH, and before the cloning of NIS, a clinical 
diagnosis of hereditary iodide transport defect (ITD) was made on the basis of goitrous hypothyroidism and absent thyroidal radioiodine uptake. 
To date, 15 mutations in the SLC5A5 gene have been identified in patients with ITD [141]. Some of these, including V59E, G93R, Δ439-443, 
R124H, Q267E, T354P, G395R, and G543E, have been studied in detail and have provided key mechanistic information on NIS function. Since 
SLC5A5 mutations are inherited in an autosomal recessive manner, NIS gene defects can be detected only when both alleles are mutated and 
the clinical picture is characterized by hypothyroidism of variable severity (from severe to fully compensated) and goiter. Furthermore, the actual 
prevalence of NIS gene mutations may be higher than that reported [142].  
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3.2 Thyroperoxidase  
The most frequent cause of dyshormonogenesis is thyroperoxidase (TPO) deficiency. TPO is the enzyme that catalyses the oxidation, 
organification, and coupling reactions. Accumulation of iodine in the thyroid gland reaches a steady state between active influx, protein binding, 
and efflux, resulting in a relatively low free intracellular iodide concentration in normal conditions, while increased in the presence of TPO 
defects. The kinetics of iodide uptake and release can be traced by administration of radioiodide. Radioiodide uptake and perchlorate inhibition 
gives an idea of the intrathyroidal iodide concentration in relation to the circulating iodine. Iodine organification defects can be quantified as total 
or partial: total iodide organification defects are characterized by discharge of more than 90% of the radioiodide taken up by the gland within 1 
hour after administration of sodium perchlorate, usually given 2 hours after radioiodide. A total disappearance of the thyroid image is also 
observed. Partial iodide organification defects are characterized by discharge of 20% to 90% of the accumulated radioiodine [143].  
Mutations in TPO gene (particularly nonsynonymous cSNPs) can lead to severe defects in thyroid hormone production, due to total or partial 
iodide organification defects. Based on the literature, exons 7–11 encoding the catalytic center of the TPO protein (heme binding region) are 
crucial for the enzymatic activity. Nonsense, splice-site, and frameshift mutations have been also described by several groups [141].  
 
3.3 DUOX1 and DUOX2 
The generation of H2O2 is a crucial step in thyroid hormonogenesis. DUOX1 and DUOX2 are glycoproteins with seven putative transmembrane 
domains. These proteins, map on chromosome 15q15.3, and their function remained unclear until a factor, named DUOXA2, which allows the 
transition of DUOX2 from the endoplasmic reticulum to the Golgi, was identified [144]. The coexpression of this factor with DUOX2 in HeLa cells 
is able to reconstitute the H2O2 production in vitro. A similar protein (DUOXA1) is necessary for the complete maturation of the DUOX1.  
In murine models, only DUOX2 loss of function mutation have been associated with hypothyroidism; thus, the role of DUOX1 in thyroid biology 
remains unclear [145]. 
DUOX2 mutations usually cause transient CH or permanent CH with partial iodide organification defect. Permanent and transient CH may result 
from both mono- and biallelic mutations, and phenotypic heterogeneity may occur with similar mutations [146]. 
To date, at least 41 patients belonging to 33 families have been reported to carry mutations in DUOX2 gene [147]. Recently, a case of CH with 
a homozygous loss-of-function mutation in DUOX1 (c.1823-1G>C) was reported. The mutation was inherited digenically with a homozygous 
DUOX2 nonsense mutation (c.1300 C>T, p. R434*) [148]. Probably, the inability of DUOX1 to compensate for the DUOX2 deficiency in these 
kindred may underlie the severe CH phenotype.  
 
3.4 Pendrin 
The Pendred syndrome is characterized by congenital neurosensorial deafness and goiter. The disease is transmitted as autosomal recessive 
disorder. Patients have a moderately enlarged thyroid gland, are usually euthyroid and show only a partial discharge of iodide after the 
administration of thiocyanate or perchlorate. The impaired hearing is not constant. In 1997, the PDS gene was cloned and the predicted protein 
of 780 amino acids (86-kD) was called Pendrin. The PDS gene maps to human chromosome 7q31, contains 21 exons, and it is expressed both 
in the cochlea and in the thyroid. Pendrin has been localized in the apical membrane of thyroid follicular cell [149]. In thyroid follicular cells, and 
in transfected oocytes, Pendrin is able to transport iodide.  
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A number of mutations in the PDS gene have been described in patients with Pendred syndrome. Despite the goiter, individuals are likely to be 
euthyroid and only rarely present congenital hypothyroidism. However, TSH levels are often in the upper limit of the normal range, and 
hypothyroidism of variable severity may eventually develop. 
In the last years, mutation in the PDS gene have also been associated with thyroid dysgenesis [135, 136]. 
 
3.5 Thyroglobulin 
Thyroglobulin is a homodimer protein synthesized exclusively in the thyroid. The human gene is located on chromosome 8q24 and the coding 
sequence, containing 8307 bp, is divided into 42 exons [150]. Patients with disorders of thyroglobulin synthesis are moderately to severely 
hypothyroid and often present goiter. Usually, plasma thyroglobulin concentration is low, especially in relation to the TSH concentrations, and 
does not change after T4 treatment or injection of TSH. Patients classified in the category “thyroglobulin synthesis defects” often have other 
abnormal iodoproteins, mainly iodinated plasma albumin, and they excrete iodopeptides of low molecular weight in the urine. At least 70 distinct 
inactivation TG gene mutations have been described [150, 151]. Scintigraphy shows high uptake (due to induction of NIS expression by TSH 
stimulation) in a typically enlarged thyroid gland.  
 
3.6 DEHAL1  
In addition to the active transport from the blood due to NIS, iodine in the thyroid follicular cells derives also from the deiodination of 
monoiodotyrosine and diiodotyrosine. The gene encoding for this enzymatic activity was recently identified and named IYD (or DEHAL1) [152]. 
The human gene maps to chromosome 6q24-q25 and consists of six exons encoding a protein of 293 amino acids, a nitroreductase-related 
enzyme capable of deiodinating iodotyrosines. In the past it has been suggested that IYD mutations could be responsible for congenital 
hypothyroidism, but only in 2008 the first IYD mutations were described in three different consanguineous families. All the patients had 
homozygous IYD mutations, and presented goiter and hypothyroidism. The onset of symptoms was very variable, either at birth or later in 
infancy or childhood. A particular mutation of IYD, (c.658G>A, p.Ala220Thr), was reported in a heterozygous 14-yr-old boy affected by 
hypothyroidism and goiter, suggesting a possible dominant effect of the mutation. Very recently, a new IYD mutation was identified by genome-
wide approach in a 20-yr-old patient with hypothyroidism and goiter and in his 4.5-yr-old apparently healthy sister in a consanguineous 
Moroccan family [153]. Since hypothyroidism is infrequent at birth, patients with biallelic IYD mutations are normally not identified as CH at the 
screening, but they subsequently came to medical attention between 1.5 and 8.0 years of age [141]. 
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Figure 1. Main steps involved in the biosynthesis of thyroid hormones. The picture schematizes the main enzymatic reactions 
involved in biosynthesis, production and release of thyroid hormones in the thyroid follicular cell. Congenital alteration in any of the 
reported steps can be associated to congenital hypothyroidism (dysormonogenesis). 
 
 
Table1-  
1. Clinical picture of the forms of congenital hypothyroidism with a genetic origin 
 
Thyroid alteration 
Thyroid 
morphology 
Gene Clinical manifestations 
Central hypothyroidism No goiter LHX3 and LHX4 
Hypothyroidism, combined pituitary hormone deficiency, short stature, 
metabolic disorders, reproductive system deficits, nervous system 
developmental abnormalities 
28 
HESX1 
Hypothyroidism, septo-optic dysplasia (SOD): hypoplasia of the optic 
nerves, various types of forebrain defects, multiple pituitary hormone 
deficiencies 
TRH and TRHR Hypothyroidism, short stature 
IGSF1 
Hypothyroidism, prolactin deficiency, macroorchidism, delayed puberty, 
neurological symptoms 
TBLX1 Congenital hypothyroidism and hearing defects 
Thyroid dysgenesis 
Athyreosis 
PAX8 No goiter, severe hypthyroidism 
NKX2-5 No goiter, severe hypothyroidism, no cardiac alterations 
FOXE1 Severe hypothyroidism, Bamforth-Lazarus syndrome 
Thyroid ectopy 
NKX2-5 No goiter, hypothyroidism, no cardiac alterations 
FOXE1 Hypothyroidism, Bamforth-Lazarus syndrome 
PAX8 Congenital hypothyroidism, non-syndromic 
DUOX2 Congenital hypothyroidism, non-syndromic 
Thyroid hypoplasia 
NKX2-1 
No goter, variable hypothyroidism (mild to severe), choreoathetosis, 
pulmonary alterations 
TSHR Reistance to TSH: no goiter, variable hypothyroidism (mild to severe) 
PAX8 No goiter, variable hypothyroidism (moderate to severe) 
Dysormonogenesis Goiter 
NIS Variable hypothyroidism (moderate to severe) 
TPO Variable hypothyroidism (moderate to severe) 
DUOX1 and 
DUOX2 
Permanent hypothyroidism (mild to severe), transient and moderate 
hypothyroidism 
DUOXA2 Variable hypothyroidism (mild to severe) 
PDS Moderate hypothyroidism and deafness; 
TG Variable hypothyroidism (from moderate to severe) 
DHEAL1 Variable hypothyroidism (mild to severe)  
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Table 2. Tests used to complete the diagnosis of CH 
 
1. Imaging studies (to determine thyroid location and size)  
 a. Scintigraphy (99mTc or 123I)  
 b. Ultrasonography  
2. Functional studies  
 a. 123I uptake  
 b. Serum thyroglobulin  
3. Suspected inborn errors of thyroid hormone synthesis  
 a. 123I uptake and perchlorate discharge  
 b. Serum/salivary/urine iodine studies  
4. Suspected autoimmune thyroid disease  
 a. Maternal and neonatal serum thyroid-antibodies determination  
5. Suspected iodine exposure (or deficiency)  
 a. Urinary iodine measurement 
